

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [except for share data]							Rupees in Lacs [except for share data]				
3 Months Period ended on December 31, 2010 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2009 [Unaudited]	9 Months Period ended on December 31, 2010 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]			3 Months Period ended on December 31, 2010 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2009 [Unaudited]	9 Months Period ended on December 31, 2010 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]
114,713	97,367	333,667	278,826	361,423	1	Sales & Income from operations :	55,047	46,527	169,676	142,426	185,491
1,258	827	4,071	2,997	4,005	A	Gross Sales	834	487	2,537	1,708	2,198
113,455	96,540	329,596	275,829	357,418	B	Less : Excise Duty	54,213	46,040	167,139	140,718	183,293
3,226	2,556	12,132	8,199	11,267	C	Net Sales	15,980	15,302	55,294	44,594	59,196
116,681	99,096	341,728	284,028	368,685	D	Other Income from Operations	70,193	61,342	222,433	185,312	242,489
(1,207)	(2,017)	(4,858)	(6,290)	(11,334)	E	Total sales and other income from operations	55,882	(1,230)	(3,810)	790	(1,080)
24,457	25,027	80,707	69,937	97,889	2	Expenditure :	15,965	17,182	55,822	49,743	70,548
12,466	7,287	27,875	25,129	31,280	A	Increase [-] / Decrease [+] in stock in trade & work in progress	3,203	2,578	10,002	7,201	7,319
14,208	11,872	40,626	33,238	44,059	B	Consumption of materials	8,512	7,051	25,509	20,264	27,790
3,335	3,336	9,518	9,410	13,389	C	Purchase of traded goods	2,465	2,239	7,218	6,540	9,004
41,140	35,933	117,541	100,082	125,924	D	Employees cost	26,317	20,755	74,221	61,061	76,924
94,399	81,438	271,409	231,506	301,207	E	Depreciation, Amortisation & Impairment	55,882	48,575	168,962	145,599	190,505
22,282	17,658	70,319	52,522	67,478	F	Other Expenditure	14,311	12,767	53,471	39,713	51,984
294	246	966	1,079	1,591	G	Total Expenditure	1,625	1,130	5,567	3,504	4,351
22,576	17,904	71,285	53,601	69,069	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	15,936	13,897	59,038	43,217	56,335
1,874	2,168	5,906	6,517	8,092	4	Other Income	878	1,035	3,046	3,357	4,263
62	(383)	789	11	122	5	Profit before Interest & Exceptional Items [3 + 4]	(130)	(150)	(120)	172	45
1,936	1,785	6,695	6,528	8,214	6	A Interest & financial charges	748	885	2,926	3,529	4,308
20,640	16,119	64,590	47,073	60,855	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	15,188	13,012	56,112	39,688	52,027
0	(114)	0	(464)	(464)	C	Total Financial cost	0	0	0	0	0
20,640	16,005	64,590	46,609	60,391	7	Profit after Interest but before Exceptional Items [5 - 6]	15,188	13,012	56,112	39,688	52,027
3,680	2,550	9,596	6,730	7,407	8	Exceptional Items [+] Income / [-] Expense	0	0	0	0	0
16,960	13,455	54,994	39,879	52,984	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	1,150	480	4,050	3,688	1,700
0	0	0	0	0	10	Tax expense	14,038	12,532	52,062	37,228	50,327
16,960	13,455	54,994	39,879	52,984	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	0	0	0	0	0
(759)	(488)	(1,791)	(1,241)	(2,470)	12	Extraordinary items [net of tax expense]	14,038	12,532	52,062	37,228	50,327
16,201	12,967	53,203	38,638	50,514	13	Net Profit [+] / Loss [-] for the period [11 - 12]	0	0	0	0	0
10,237	6,824	10,237	6,824	6,824	14	Adjustments on consolidation [+] Income / [-] Expense	14,038	12,532	52,062	37,228	50,327
				156,030	15	Net Profit [+] / Loss [-] for the period [13 + 14]	14,038	12,532	52,062	37,228	50,327
7.91	6.33 *	25.98	18.87 *	24.67 *	16	Paid-up equity share capital [Face Value Rs. 5/-]	10,237	6,824	10,237	6,824	6,824
7.91	6.33 *	25.98	18.87 *	24.67 *	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	6.86	6.12 *	25.43	18.18 *	24.58 *
51,610,474	34,406,982	51,610,474	34,406,982	34,406,982	18	Earnings Per Share [EPS] [For the period - not Annualised]:	6.86	6.12 *	25.43	18.18 *	24.58 *
25.21%	25.21%	25.21%	25.21%	25.21%	A	Basic and Diluted EPS before Extraordinary items [Rs.]	6.86	6.12 *	25.43	18.18 *	24.58 *
					B	Basic and Diluted EPS after Extraordinary items [Rs.]	6.86	6.12 *	25.43	18.18 *	24.58 *
NII	NII	NII	NII	NII	19	Public shareholding :	51,610,474	34,406,982	51,610,474	34,406,982	34,406,982
N.A.	N.A.	N.A.	N.A.	N.A.		- Number of shares	25.21%	25.21%	25.21%	25.21%	25.21%
N.A.	N.A.	N.A.	N.A.	N.A.		- Percentage of Shareholding	153,138,046	102,092,031	153,138,046	102,092,031	102,092,031
153,138,046	102,092,031	153,138,046	102,092,031	102,092,031	20	Promoters and Promoter group Shareholding :	100%	100.00%	100%	100%	100.00%
74.79%	74.79%	74.79%	74.79%	74.79%	A	Pledged / Encumbered :	74.79%	74.79%	74.79%	74.79%	74.79%
						- Number of Shares	NII	NII	NII	NII	NII
						- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	N.A.
						- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	N.A.
					B	Non-encumbered :	153,138,046	102,092,031	153,138,046	102,092,031	102,092,031
						- Number of Shares	100%	100.00%	100%	100%	100.00%
						- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	74.79%	74.79%	74.79%	74.79%	74.79%
						- Percentage of shares [as a % of the total share capital of the company]	74.79%	74.79%	74.79%	74.79%	74.79%

Notes :

- [1] The above results for the quarter 31, 2010 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on January 18, 2011.
- [2]* Earning per share in item 1 (nine months period ended on December 31, 2009 & previous accounting year ended on March 31, 2010) is calculated taking into account the allotment issued by the company, to make the figures comparable.
- [3] The changes in Investments as under :
Zydus BSV Pharma Investment] Rs. 110 Lacs
- [4] The status of investor company
Pending at the beginning of and disposed off during the quarter - 30, pending at the end of the quarter - Nil
- [5] The Company has one segment "Pharmaceuticals".

Ahmedabad, January 18, 2011

For Cadila Healthcare Limited,



Pankaj R. Patel
Chairman & Managing Director